Gemer PR Tablets combine Glimepiride, a sulfonylurea that stimulates insulin release, and Metformin, a biguanide that reduces glucose production in the liver and improves insulin sensitivity. The prolonged-release (PR) formulation of Metformin ensures sustained blood sugar control throughout the day. This dual-action antidiabetic medication is prescribed for patients with type 2 diabetes mellitus who are unable to achieve optimal glycemic control with single-agent therapy.

• Dual mechanism of action for better blood sugar control

• Helps lower both fasting and postprandial glucose levels

• Convenient once-daily dosing with prolonged-release technology

• Supports improved insulin efficiency and beta-cell activity

• Enhances patient adherence due to combination therapy in one tablet

• Take the tablet once daily with breakfast or the first main meal

• Swallow whole with water; do not crush, split, or chew

• Use exactly as prescribed by your healthcare provider

• Combine with dietary management and physical activity for best results

• Typical starting dose: As directed by a physician, depending on prior treatment

• Dosage adjustments may be made gradually to minimize the risk of hypoglycemia

• Do not take more than the prescribed amount

• If a dose is missed, take it as soon as you remember—skip if it's close to the next dose

• Not suitable for patients with type 1 diabetes or diabetic ketoacidosis

• Use with caution in patients with renal or hepatic impairment

• Regular monitoring of blood glucose, renal function, and liver enzymes is recommended

• Avoid alcohol consumption to reduce the risk of lactic acidosis

• Not recommended during pregnancy or lactation unless advised by a doctor

• Common:

• Nausea or stomach upset

• Headache

• Serious (rare):

• Severe hypoglycemia

• Lactic acidosis

• Allergic skin reactions

• Liver enzyme elevation

•  

• Dizziness

• Mild hypoglycemia (especially with irregular meals)